A citation-based method for searching scientific literature

K V S Hari Kumar, Altamash Shaikh, Pitambar Prusty. Diabetes Res Clin Pract 2013
Times Cited: 59



Yunjuan Zhao, Lin Yang, Yufei Xiang, Lingjiao Liu, Gan Huang, Zhaofeng Long, Xia Li, R David Leslie, Xiangbing Wang, Zhiguang Zhou. J Clin Endocrinol Metab 2014
Times Cited: 69




List of shared articles



Times cited

Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes.
Marc Evans, Debbie Hicks, Dipesh Patel, Vinod Patel, Phil McEwan, Umesh Dashora. Diabetes Ther 2020
11

The efficacy and safety of DPP4 inhibitors in patients with type 1 diabetes: A systematic review and meta-analysis.
Heming Guo, Chen Fang, Yun Huang, Yufang Pei, Linqi Chen, Ji Hu. Diabetes Res Clin Pract 2016
32

Incretin-based therapies for patients with type 1 diabetes: a meta-analysis.
Lili Liu, Zhuo Shao, Ying Xia, Jiabi Qin, Yang Xiao, Zhiguang Zhou, Zubing Mei. Endocr Connect 2019
6

Sitagliptin inhibit human lymphocytes proliferation and Th1/Th17 differentiation in vitro.
Marcelo Maia Pinheiro, Caroline Lais Stoppa, Claudete Justina Valduga, Cristina Eunice Okuyama, Renata Gorjão, Regina Mara Silva Pereira, Susana Nogueira Diniz. Eur J Pharm Sci 2017
38

Combined treatment with sitagliptin and vitamin D in a patient with latent autoimmune diabetes in adults.
E Rapti, S Karras, M Grammatiki, A Mousiolis, X Tsekmekidou, E Potolidis, P Zebekakis, M Daniilidis, K Kotsa. Endocrinol Diabetes Metab Case Rep 2016
20

Using DPP-4 inhibitors to modulate beta cell function in type 1 diabetes and in the treatment of diabetic kidney disease.
Hugh Davis, Vanessa Jones Briscoe, Sofio Dumbadze, Stephen N Davis. Expert Opin Investig Drugs 2019
3

Combination of vitamin D and dipeptidyl peptidase-4 inhibitors (VIDPP-4i) as an immunomodulation therapy for autoimmune diabetes.
Marcelo Maia Pinheiro, Felipe Moura Maia Pinheiro, Susana Nogueira Diniz, Andrea Fabbri, Marco Infante. Int Immunopharmacol 2021
1

Emerging Roles of Dipeptidyl Peptidase-4 Inhibitors in Delaying the Progression of Type 1 Diabetes Mellitus.
Jaquellyne Gurgel Penaforte-Saboia, Carlos Eduardo Barra Couri, Natasha Vasconcelos Albuquerque, Vanessa Lauanna Lima Silva, Natália Bitar da Cunha Olegario, Virgínia Oliveira Fernandes, Renan Magalhães Montenegro Junior. Diabetes Metab Syndr Obes 2021
1

DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
Qixian Wang, Min Long, Hua Qu, Rufei Shen, Rui Zhang, Jing Xu, Xin Xiong, Hui Wang, Hongting Zheng. J Diabetes Res 2018
19

Four-year clinical remission of type 1 diabetes mellitus in two patients treated with sitagliptin and vitamin D3.
Marcelo Maia Pinheiro, Felipe Moura Maia Pinheiro, Margareth Afonso Torres. Endocrinol Diabetes Metab Case Rep 2016
14

Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions.
Shiying Shao, QinQin Xu, Xuefeng Yu, Ruping Pan, Yong Chen. Pharmacol Ther 2020
26

Efficacy and safety of incretin-based drugs in patients with type 1 diabetes mellitus: A systematic review and meta-analysis.
Wen Wang, Yun Gao, Dawei Chen, Chun Wang, Xiaobing Feng, Xingwu Ran. Diabetes Res Clin Pract 2017
6




Adjunct therapies in treatment of type 1 diabetes.
Itivrita Goyal, Alamgir Sattar, Megan Johnson, Paresh Dandona. J Diabetes 2020
2

SGLT inhibitor adjunct therapy in type 1 diabetes.
Rory J McCrimmon, Robert R Henry. Diabetologia 2018
39

Dipeptidyl peptidase-4(DPP-4) inhibitors: promising new agents for autoimmune diabetes.
Xia Wang, Peilin Zheng, Gan Huang, Lin Yang, Zhiguang Zhou. Clin Exp Med 2018
11